Atea Pharmaceuticals, Inc.
AVIR
$4.49
$0.143.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 41.13M | 47.60M | 38.23M | 32.35M | 28.35M |
| Gross Profit | -41.13M | -47.60M | -38.23M | -32.35M | -28.35M |
| SG&A Expenses | 6.87M | 7.12M | 7.22M | 9.07M | 9.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.01M | 54.71M | 45.45M | 41.42M | 37.81M |
| Operating Income | -48.01M | -54.71M | -45.45M | -41.42M | -37.81M |
| Income Before Tax | -45.39M | -51.64M | -41.85M | -36.95M | -34.07M |
| Income Tax Expenses | 50.00K | -6.77M | 196.00K | 207.00K | 203.00K |
| Earnings from Continuing Operations | -45.44M | -44.87M | -42.05M | -37.16M | -34.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.44M | -44.87M | -42.05M | -37.16M | -34.27M |
| EBIT | -48.01M | -54.71M | -45.45M | -41.42M | -37.81M |
| EBITDA | -47.90M | -54.61M | -45.35M | -41.32M | -37.70M |
| EPS Basic | -0.57 | -0.57 | -0.53 | -0.44 | -0.40 |
| Normalized Basic EPS | -0.36 | -0.41 | -0.33 | -0.28 | -0.24 |
| EPS Diluted | -0.57 | -0.57 | -0.53 | -0.44 | -0.40 |
| Normalized Diluted EPS | -0.36 | -0.41 | -0.33 | -0.28 | -0.24 |
| Average Basic Shares Outstanding | 79.20M | 78.13M | 79.05M | 83.75M | 85.16M |
| Average Diluted Shares Outstanding | 79.20M | 78.13M | 79.05M | 83.75M | 85.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |